Payment overview · 2025
General Payments
$1,495.68
94 reported records · 18 companies
Healthcare provider profile · identity verified
Gregory V. Maynard, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAINT JAMES, MO · NPI 1063450187
Verified facts
What the public records show
CMS Open Payments records show Gregory V. Maynard, D.O. received $1,495.68 in general payments during 2025 across 94 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $305.87 | 20.4% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $161.55 | 10.8% | 16 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $155.29 | 10.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.53 | 9.8% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $134.80 | 9.0% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.59 | 6.9% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.24 | 5.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.30 | 4.9% | 4 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $65.10 | 4.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.64 | 3.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.29 | 3.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.85 | 3.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.14 | 2.8% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.33 | 1.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.96 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.69 | 1.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.62 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.89 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,495.68 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $260.48 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $211.04 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $161.55 | 16 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $156.59 | 15 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $155.29 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.77 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.04 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.30 | 4 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $65.10 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.96 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $55.29 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.29 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.39 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.14 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.11 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 18 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 136 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 111 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
98 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
111 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
237 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1198 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 930 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 893 | 214 |
| Gabapentin | Gabapentin | 702 | 137 |
| Alprazolam | Alprazolam | 603 | 82 |
| Lisinopril | Lisinopril | 601 | 146 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 588 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 531 | 129 |
| Omeprazole | Omeprazole | 525 | 128 |
| Losartan Potassium | Losartan Potassium | 510 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 434 | 97 |
| Potassium Chloride | Potassium Chloride | 432 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 425 | 98 |
| Metformin Hcl | Metformin Hcl | 415 | 99 |
| Tramadol Hcl | Tramadol Hcl | 394 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 383 | 84 |
| Simvastatin | Simvastatin | 365 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 325 | 73 |
| Furosemide | Furosemide | 323 | 79 |
| Famotidine | Famotidine | 309 | 66 |
| Trazodone Hcl | Trazodone Hcl | 298 | 55 |
| Oxycodone Hcl | Oxycodone Hcl | 297 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 282 | 70 |
| Montelukast Sodium | Montelukast Sodium | 271 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 259 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 248 | 57 |
| Sertraline Hcl | Sertraline Hcl | 245 | 49 |
| Eliquis | Apixaban | 237 | 43 |
| Chlorthalidone | Chlorthalidone | 234 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 234 | 44 |
| Baclofen | Baclofen | 233 | 41 |
| Buspirone Hcl | Buspirone Hcl | 222 | 41 |
| Pregabalin | Pregabalin | 222 | 38 |
| Ezetimibe | Ezetimibe | 213 | 54 |
| Glipizide | Glipizide | 212 | 49 |
| Morphine Sulfate Er | Morphine Sulfate | 210 | 22 |
| Prednisone | Prednisone | 202 | 109 |
| Carvedilol | Carvedilol | 199 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 44 |
| Topiramate | Topiramate | 174 | 29 |
| Mirtazapine | Mirtazapine | 173 | 43 |
| Warfarin Sodium | Warfarin Sodium | 159 | 19 |
| Atenolol | Atenolol | 156 | 40 |
| Spironolactone | Spironolactone | 154 | 46 |
| Bumetanide | Bumetanide | 150 | 36 |
| Meloxicam | Meloxicam | 146 | 40 |
| Allopurinol | Allopurinol | 142 | 34 |
| Celecoxib | Celecoxib | 140 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 138 | 28 |
| Jardiance | Empagliflozin | 136 | 29 |
| Clonazepam | Clonazepam | 127 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 116 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 115 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 111 | 29 |
| Repatha Sureclick | Evolocumab | 111 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 22 |
| Fenofibrate | Fenofibrate | 104 | 25 |
| Glimepiride | Glimepiride | 103 | 28 |
| Lorazepam | Lorazepam | 103 | 20 |
| Linzess | Linaclotide | 98 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 98 | 20 |
| Mounjaro | Tirzepatide | 96 | 18 |
| Farxiga | Dapagliflozin Propanediol | 94 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 12 |
| Lamotrigine | Lamotrigine | 90 | 14 |
| Vascepa | Icosapent Ethyl | 90 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 20 |
| Metformin Hcl Er | Metformin Hcl | 82 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 81 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 16 |
| Propranolol Hcl | Propranolol Hcl | 76 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 17 |
| Ozempic | Semaglutide | 71 | 19 |
| Sucralfate | Sucralfate | 71 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 71 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 16 |
| Glipizide Er | Glipizide | 68 | 16 |
| Rybelsus | Semaglutide | 65 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 64 | 15 |
| Diazepam | Diazepam | 63 | 15 |
| Lovastatin | Lovastatin | 63 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 62 | 11 |
| Ibuprofen | Ibuprofen | 62 | 14 |
| Fluconazole | Fluconazole | 59 | 33 |
| Naproxen | Naproxen | 59 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 58 | suppressed |
| Nystatin | Nystatin | 57 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | suppressed |
| Ondansetron Odt | Ondansetron | 56 | 14 |
| Levetiracetam | Levetiracetam | 55 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Zaleplon | Zaleplon | 54 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 52 | 12 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 16 |
| Phenobarbital | Phenobarbital | 48 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 48 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 14 |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 40 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Finasteride | Finasteride | 38 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Ramipril | Ramipril | 35 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 25 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Azelastine Hcl | Azelastine Hcl | 31 | 11 |
| Metolazone | Metolazone | 31 | 14 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 12 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 25 |
| Cefdinir | Cefdinir | 26 | 22 |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Triazolam | Triazolam | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Lyrica | Pregabalin | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Trimethoprim | Trimethoprim | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Xtampza Er | Oxycodone Myristate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Cefprozil | Cefprozil | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,495.68 · 94 records | ABBVIE INC. | AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, SMARTVEST, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error